Press Releases

Dated: Monday 19 October 2009

Comment from Ian Carr, Joint Administrator of Alizyme plc and Alizyme Therapeutics Limited

“Further to the announcement on Friday 16th October of the sale of cetilistat to Norgine BV and dividend prospects for shareholders, it should be noted that the Statement of Affairs of Alizyme plc included in the administrators’ proposals dated 17 September 2009 reflected the position of that company and the directors’ best estimates of the realisable value of the assets at the time it went in to administration. As stated in the announcement any future dividend potentially available to shareholders will be subject to the adjudication of creditors claims. Claims will be adjudicated by a subsequently appointed liquidator of each of Alizyme plc and Alizyme Therapeutics Limited and will also be subject to any tax payable and costs of realisation.”

Grant Thornton UK LLP is a leading financial and business adviser with 30 locations nationwide. We are the UK member of Grant Thornton International, one of the world's leading international organisations of independently owned and managed accounting and consulting firms. Although Grant Thornton International is not a worldwide partnership, the firms share a commitment to providing the same high quality service to their clients wherever they do business.

Copyright © 2009 Grant Thornton UK LLP. All rights reserved.

Grant Thornton - advisers to the independently minded – www.grantthornton.co.uk

Back